These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 9041667

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults.
    Paradis EM, Tikhonov O, Cao X, Kharit SM, Fokin A, Platt HL, Banniettis N.
    Hum Vaccin Immunother; 2021 Nov 02; 17(11):4177-4182. PubMed ID: 34473594
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.
    Dubey AP, Faridi MMA, Mitra M, Kaur IR, Dabas A, Choudhury J, Mukherjee M, Mishra D.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2032-2037. PubMed ID: 28509605
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children.
    Ngai AL, Staehle BO, Kuter BJ, Cyanovich NM, Cho I, Matthews H, Keller P, Arvin AM, Watson B, White CJ.
    Pediatr Infect Dis J; 1996 Jan 02; 15(1):49-54. PubMed ID: 8684876
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®.
    Reisinger KS, Richardson E, Malacaman EA, Levin MJ, Gardner JL, Wang W, Stek JE, Kuter B.
    Vaccine; 2019 Sep 10; 37(38):5788-5795. PubMed ID: 30146405
    [Abstract] [Full Text] [Related]

  • 12. Antibody assays suitable for assessing immune responses to live varicella vaccine.
    Provost PJ, Krah DL, Kuter BJ, Morton DH, Schofield TL, Wasmuth EH, White CJ, Miller WJ, Ellis RW.
    Vaccine; 1991 Feb 10; 9(2):111-6. PubMed ID: 1647574
    [Abstract] [Full Text] [Related]

  • 13. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine.
    Watson B, Gupta R, Randall T, Starr S.
    J Infect Dis; 1994 Jan 10; 169(1):197-9. PubMed ID: 8277182
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children.
    Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY, Lin TY, Lee BW, Kwan K, Kasim SM, Chan CY, Kaplan KM, Distefano DJ, Harmon AL, Golie A, Hartzel J, Xu J, Li S, Matthews H, Sadoff JC, Shaw A.
    Vaccine; 2002 Jul 26; 20(23-24):2942-9. PubMed ID: 12126906
    [Abstract] [Full Text] [Related]

  • 18. [A study for the necessity of virus titer of varicella vaccine presently used].
    Ozaki T, Nishimura N, Gotoh K, Funahashi K.
    Kansenshogaku Zasshi; 2012 Nov 26; 86(6):749-54. PubMed ID: 23367850
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group.
    Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H, Provost PJ, White CJ.
    Vaccine; 1995 Aug 26; 13(11):967-72. PubMed ID: 8525689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.